+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Market Spotlight: Eating Disorders

  • Report
  • 32 Pages
  • April 2021
  • Region: Global
  • Pharma Intelligence
  • ID: 4533534
This Market Spotlight report covers the Eating Disorders market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, probability of success, a 10-year disease prevalence forecast, and as well as presenting drug-specific revenue forecasts.

Key Takeaways
  • Worldwide, the publisher estimates that in 2017, there were approximately 35.6 million prevalent cases of eating disorders in females aged 10–19 years, including 3.0 million cases of anorexia nervosa, 11.6 million cases of bulimia nervosa, and 14.3 million cases of binge eating disorder.
  • In this demographic group, the publisher forecasts the number of prevalent cases of eating disorders to increase to 38.1 million by 2026.
  • Edgemont’s Fluoxetine Tablets, Eli Lilly’s Prozac, and Takeda’s Vyvanse are the only FDA-approved drugs for eating disorders. These drugs are administered via the oral route, with Vyvanse also available in an intranasal formulation.
  • There are only two industry-sponsored drugs in active clinical development for eating disorders, both of which are in Phase II. Therapies in active clinical development for eating disorders target hypocretin/orexin receptor and ghrelin receptor. These therapies are being tested as oral and subcutaneous formulations.
  • The overall likelihood of approval of a Phase I eating disorders asset is 8.9%, and the average probability a drug advances from Phase III is 66.7%. Drugs, on average, take 5.8 years from Phase I to approval, compared to 9.3 years in the overall psychiatry space.
  • All of the clinical trials for eating disorders have been in Phase III. The US leads in terms of the number of eating disorders clinical trials globally, while Germany leads the major European markets.
  • Clinical trial activity in the eating disorders space consists entirely of completed trials. Takeda has the highest number of completed clinical trials for eating disorders, with three trials.
  • Takeda leads industry sponsors with the highest number of Phase III clinical trials for eating disorders, followed by Johnson & Johnson

Table of Contents

OVERVIEWKEY TAKEAWAYS
DISEASE BACKGROUND
  • Subtypes

TREATMENT
  • Psychotherapy
  • Medications

EPIDEMIOLOGYMARKETED DRUGSPIPELINE DRUGSPROBABILITY OF SUCCESSREVENUE OPPORTUNITY
CLINICAL TRIAL LANDSCAPE
  • Sponsors by status
  • Sponsors by phase

BIBLIOGRAPHYAPPENDIX
LIST OF FIGURES
Figure 1: Trends in worldwide prevalent cases of eating disorders in females aged 10–19 years, 2017–26
Figure 2: Overview of pipeline drugs for eating disorders in the US
Figure 3: Pipeline drugs for eating disorders, by company
Figure 4: Pipeline drugs for eating disorders, by drug type
Figure 5: Pipeline drugs for eating disorders, by classification
Figure 6: Probability of success in the eating disorders pipeline
Figure 7: Clinical trials in eating disorders
Figure 8: Top 10 drugs for clinical trials in eating disorders
Figure 9: Top 10 companies for clinical trials in eating disorders
Figure 10: Trial locations in eating disorders
Figure 11: Eating disorders trials status
Figure 12: Eating disorders trials sponsors, by phase
LIST OF TABLES
Table 1: Worldwide prevalent cases of eating disorders in females aged 10–19 years, 2017–26
Table 2: Prevalent cases of eating disorders in females aged 10–19 years in Africa, 2017–26
Table 3: Prevalent cases of eating disorders in females aged 10–19 years in Asia, 2017–26
Table 4: Prevalent cases of eating disorders in children aged 10–19 years in Latin America and the Caribbean, 2017–26
Table 5: Prevalent cases of eating disorders in children aged 10–19 years in Northern America, 2017–26
Table 6: Prevalent cases of eating disorders in children aged 10–19 years in Oceania, 2017–26
Table 7: Prevalent cases of eating disorders in all ages in Europe, 2017–26
Table 8: Marketed drugs for eating disorders
Table 9: Pipeline drugs for eating disorders in the US
Table 10: Historical global sales, by drug ($m), 2016–20
Table 11: Forecasted global sales, by drug ($m), 2021–25